Nutcracker Therapeutics Inc., a startup developing a "push-button GMP-in-a-box" platform to manufacture mRNA therapeutics, has raised $60 million in series B financing led by Arch Venture Partners.

Immune Regulation Ltd., a U.S.-U.K. venture advancing peptide-based therapies for rheumatoid arthritis and allergic diseases, has closed a £40.6 million (US$53.4 million) series B financing that will support its preparation for multiple phase II studies next year, as well as an evaluation of one candidate in COVID-19-related acute respiratory distress syndrome. Morningside Ventures led the round, along with existing shareholders, including London-based 24Haymarket.

Outset Medical Inc. closed its Nasdaq IPO Thursday with gross proceeds of approximately of $277.9 million. The IPO, which launched Tuesday, included nearly 10.3 million shares of common stock at $27 per share and the full exercise of underwriters’ option to purchase more than 1.3 million additional shares. Shares of the San Jose, Calif.-based company’s stock, which is trading under the ticker OM, soared to more than $60 on the first day of trading amid enthusiasm for its portable dialysis machine.